US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...
MM&M20h
Rx Rundown: Roche, Metsera, Intercept Pharmaceuticals and more
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom
United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.